GENETIX Pharmaceuticals Garners $35,000,000 Series B Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c2a3c4b2-67ad-40c6-8f8f-58d20b4be0af&Preview=1 -
Date
3/12/2010 -
Company Name
GENETIX Pharmaceuticals -
Mailing Address
840 Memorial Drive Cambridge, MA 02139 -
Company Description
GENETIX’ LentiGlobin hemoglobin gene therapy utilizes a highly modified human lentivirus to deliver a corrective version of the native beta-globin gene to the chromosomes of blood stem cells, found in large numbers in bone marrow. -
Website
http://www.genetixpharm.com -
Transaction Type
Venture Equity -
Transaction Amount
$35,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team. -
M&A Terms
-
Venture Investor
Third Rock Ventures -
Venture Investor
Genzyme Ventures -
Venture Investor
TVM Capital -
Venture Investor
Forbion Capital Partners -
Venture Investor
Easton Hunt Capital Partners
